Erasca Inc Net Income per Employee (ERAS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Erasca Inc   (NASDAQ: ERAS)
 

Erasca Inc Net Income per Employee

ERAS's Quarterly Results, Trends, Rankings, Statistics
Erasca Inc recorded a cumulative net loss of $-287 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 382 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4084, from total ranking in previous quarter at 4565.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ERAS Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,788,573 -2,689,515 -1,209,184 -1,239,670 -1,245,379
ERAS's Total Ranking # 4084 # 4565 # 4022 # 4089 # 4197
Seq. Net Income Change - - - - -

ERAS Company Profile >> Back to ERAS Efficiency Comparisons >> Compare ERAS Net Income per Employee to its Competitors

ERAS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 383
Healthcare Sector # 830
Overall Market # 4084

Net Income per Employee Statistics
High Average Low
$ -273,922 $ -1,612,775 $ -2,788,573
(Jun 30 2021)   (Jun 30 2026)




  News about Erasca Inc Income per employee

Erasca Raises $184 Million in Oversubscribed Underwritten Offering to Advance Precision Oncology Therapies


SAN DIEGO, May 21, 2024 Erasca Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company specializing in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, has successfully concluded its oversubscribed underwritten offering. The company announced the closure of this offering, which included the full exercise of the underwriters option to purchase additional shares, resulting in the sale of 99,459,458 shares of its common stock. Priced at $1.85 per share, the gross proceeds to Erasca from this offering amounted to approximately $184.0 million.
Erasca s primary focus is on developing innovative treatment solutions for patients with RAS/MAPK pathway-driven cancers, a broad range of aggressive malignancies that have been historically challenging to treat effectively. By capitalizing on precision oncology, Erasca aims to revolutionize cancer care by targeting the underlying genetic abnormalities that drive tumor growth.

Erasca Announces Successful $45 Million Oversubscribed Private Placement Financing, Bolstering Company's Growth Prospects

1. Funding Extends Erasca s Cash Runway as Company Records Net Loss
Erasca Inc, a leading biotechnology company focused on developing precision oncology therapies, has recently announced an extension of its anticipated cash runway through the second half of 2026. This significant funding comes from a combination of new and existing investors, highlighting the confidence in the company s potential.
According to Erasca s financial report, the company revealed a cumulative net loss of $221 million during the 12-month period ending in the third quarter of 2023. Despite this staggering figure, Erasca s management remains optimistic about the future of the company and its ability to revolutionize cancer treatment.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-08T17:35:13+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.